PYNNACLE phase II clinical trial protocol: rezatapopt (PC14586) monotherapy in advanced or metastatic solid tumors with a TP53 Y220C mutation
PYNNACLE II期临床试验方案：rezatapopt (PC14586) 单药治疗携带 TP53 Y220C 突变的晚期或转移性实体瘤
期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2025.2557176
Schram, Alison M; Fellous, Marc; LeDuke, Kim; Schmid, Anita; Dumbrava, Ecaterina E
